nodes	percent_of_prediction	percent_of_DWPC	metapath
Pethidine—CYP2C19—Teniposide—lymphatic system cancer	0.111	0.334	CbGbCtD
Pethidine—CYP3A4—Cytarabine—lymphatic system cancer	0.0543	0.164	CbGbCtD
Pethidine—CYP3A4—Teniposide—lymphatic system cancer	0.0535	0.161	CbGbCtD
Pethidine—ALB—Methotrexate—lymphatic system cancer	0.0497	0.15	CbGbCtD
Pethidine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0374	0.113	CbGbCtD
Pethidine—Fibrosis—Fludarabine—lymphatic system cancer	0.0324	0.0485	CcSEcCtD
Pethidine—Neurotoxicity—Teniposide—lymphatic system cancer	0.0272	0.0407	CcSEcCtD
Pethidine—CYP3A4—Vincristine—lymphatic system cancer	0.0257	0.0777	CbGbCtD
Pethidine—Neurotoxicity—Fludarabine—lymphatic system cancer	0.0239	0.0358	CcSEcCtD
Pethidine—Fibrosis—Carmustine—lymphatic system cancer	0.0208	0.031	CcSEcCtD
Pethidine—Induration—Bleomycin—lymphatic system cancer	0.0152	0.0227	CcSEcCtD
Pethidine—Neurotoxicity—Vincristine—lymphatic system cancer	0.0146	0.0218	CcSEcCtD
Pethidine—Pallor—Teniposide—lymphatic system cancer	0.0127	0.019	CcSEcCtD
Pethidine—Fibrosis—Methotrexate—lymphatic system cancer	0.00961	0.0144	CcSEcCtD
Pethidine—Myoclonus—Vincristine—lymphatic system cancer	0.00941	0.0141	CcSEcCtD
Pethidine—Phlebitis—Teniposide—lymphatic system cancer	0.00889	0.0133	CcSEcCtD
Pethidine—Paranoia—Carmustine—lymphatic system cancer	0.0087	0.013	CcSEcCtD
Pethidine—Coma—Fludarabine—lymphatic system cancer	0.00847	0.0127	CcSEcCtD
Pethidine—Paralysis—Vincristine—lymphatic system cancer	0.00815	0.0122	CcSEcCtD
Pethidine—Anuria—Methotrexate—lymphatic system cancer	0.00786	0.0118	CcSEcCtD
Pethidine—Phlebitis—Fludarabine—lymphatic system cancer	0.00781	0.0117	CcSEcCtD
Pethidine—Injection site pain—Carmustine—lymphatic system cancer	0.00727	0.0109	CcSEcCtD
Pethidine—Visual disturbance—Fludarabine—lymphatic system cancer	0.0071	0.0106	CcSEcCtD
Pethidine—Neurotoxicity—Methotrexate—lymphatic system cancer	0.00709	0.0106	CcSEcCtD
Pethidine—Coordination abnormal—Carmustine—lymphatic system cancer	0.00604	0.00903	CcSEcCtD
Pethidine—Depressed level of consciousness—Carmustine—lymphatic system cancer	0.00573	0.00857	CcSEcCtD
Pethidine—Phlebitis—Bleomycin—lymphatic system cancer	0.00573	0.00856	CcSEcCtD
Pethidine—Sweating—Teniposide—lymphatic system cancer	0.00566	0.00846	CcSEcCtD
Pethidine—Vertigo—Mechlorethamine—lymphatic system cancer	0.00562	0.0084	CcSEcCtD
Pethidine—Disorientation—Bleomycin—lymphatic system cancer	0.00551	0.00825	CcSEcCtD
Pethidine—Coma—Carmustine—lymphatic system cancer	0.00542	0.00811	CcSEcCtD
Pethidine—Coma—Vincristine—lymphatic system cancer	0.00517	0.00774	CcSEcCtD
Pethidine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0051	0.00763	CcSEcCtD
Pethidine—Phlebitis—Carmustine—lymphatic system cancer	0.005	0.00747	CcSEcCtD
Pethidine—Flushing—Teniposide—lymphatic system cancer	0.00492	0.00735	CcSEcCtD
Pethidine—Anorexia—Mechlorethamine—lymphatic system cancer	0.00486	0.00728	CcSEcCtD
Pethidine—Phlebitis—Mitoxantrone—lymphatic system cancer	0.00465	0.00695	CcSEcCtD
Pethidine—Visual impairment—Fludarabine—lymphatic system cancer	0.00449	0.00671	CcSEcCtD
Pethidine—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00444	0.00663	CcSEcCtD
Pethidine—Agitation—Teniposide—lymphatic system cancer	0.00424	0.00634	CcSEcCtD
Pethidine—Hypertension—Teniposide—lymphatic system cancer	0.00398	0.00595	CcSEcCtD
Pethidine—Paralysis—Methotrexate—lymphatic system cancer	0.00395	0.00591	CcSEcCtD
Pethidine—Urinary retention—Vincristine—lymphatic system cancer	0.00391	0.00585	CcSEcCtD
Pethidine—Cardiac arrest—Vincristine—lymphatic system cancer	0.00391	0.00585	CcSEcCtD
Pethidine—Confusional state—Teniposide—lymphatic system cancer	0.00379	0.00567	CcSEcCtD
Pethidine—Oedema—Teniposide—lymphatic system cancer	0.00376	0.00563	CcSEcCtD
Pethidine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00376	0.00562	CcSEcCtD
Pethidine—Agitation—Fludarabine—lymphatic system cancer	0.00372	0.00557	CcSEcCtD
Pethidine—Tachycardia—Teniposide—lymphatic system cancer	0.00367	0.00549	CcSEcCtD
Pethidine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00364	0.00544	CcSEcCtD
Pethidine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00361	0.0054	CcSEcCtD
Pethidine—Anorexia—Teniposide—lymphatic system cancer	0.00359	0.00536	CcSEcCtD
Pethidine—Hypotension—Teniposide—lymphatic system cancer	0.00352	0.00526	CcSEcCtD
Pethidine—Convulsion—Fludarabine—lymphatic system cancer	0.00351	0.00525	CcSEcCtD
Pethidine—Confusional state—Fludarabine—lymphatic system cancer	0.00333	0.00499	CcSEcCtD
Pethidine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00331	0.00495	CcSEcCtD
Pethidine—Oedema—Fludarabine—lymphatic system cancer	0.00331	0.00495	CcSEcCtD
Pethidine—Decreased appetite—Teniposide—lymphatic system cancer	0.00327	0.00489	CcSEcCtD
Pethidine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00325	0.00485	CcSEcCtD
Pethidine—Rash—Mechlorethamine—lymphatic system cancer	0.00322	0.00481	CcSEcCtD
Pethidine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00322	0.00481	CcSEcCtD
Pethidine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.0032	0.00478	CcSEcCtD
Pethidine—Flushing—Bleomycin—lymphatic system cancer	0.00317	0.00474	CcSEcCtD
Pethidine—Anorexia—Fludarabine—lymphatic system cancer	0.00315	0.00471	CcSEcCtD
Pethidine—Feeling abnormal—Teniposide—lymphatic system cancer	0.0031	0.00464	CcSEcCtD
Pethidine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00308	0.00461	CcSEcCtD
Pethidine—Sweating—Vincristine—lymphatic system cancer	0.00304	0.00454	CcSEcCtD
Pethidine—Nausea—Mechlorethamine—lymphatic system cancer	0.00303	0.00453	CcSEcCtD
Pethidine—Urticaria—Teniposide—lymphatic system cancer	0.00299	0.00447	CcSEcCtD
Pethidine—Erythema—Bleomycin—lymphatic system cancer	0.00297	0.00444	CcSEcCtD
Pethidine—Hallucination—Carmustine—lymphatic system cancer	0.00296	0.00443	CcSEcCtD
Pethidine—Sweating—Mitoxantrone—lymphatic system cancer	0.00296	0.00442	CcSEcCtD
Pethidine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00287	0.0043	CcSEcCtD
Pethidine—Visual impairment—Carmustine—lymphatic system cancer	0.00287	0.00429	CcSEcCtD
Pethidine—Hallucination—Vincristine—lymphatic system cancer	0.00283	0.00423	CcSEcCtD
Pethidine—Constipation—Fludarabine—lymphatic system cancer	0.00283	0.00423	CcSEcCtD
Pethidine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00282	0.00422	CcSEcCtD
Pethidine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00277	0.00415	CcSEcCtD
Pethidine—Flushing—Carmustine—lymphatic system cancer	0.00276	0.00413	CcSEcCtD
Pethidine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00273	0.00408	CcSEcCtD
Pethidine—Asthenia—Teniposide—lymphatic system cancer	0.0027	0.00404	CcSEcCtD
Pethidine—Pruritus—Teniposide—lymphatic system cancer	0.00266	0.00398	CcSEcCtD
Pethidine—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00265	0.00397	CcSEcCtD
Pethidine—Erythema—Carmustine—lymphatic system cancer	0.00259	0.00388	CcSEcCtD
Pethidine—Coma—Methotrexate—lymphatic system cancer	0.00251	0.00375	CcSEcCtD
Pethidine—Confusional state—Bleomycin—lymphatic system cancer	0.00244	0.00366	CcSEcCtD
Pethidine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00244	0.00364	CcSEcCtD
Pethidine—Tremor—Carmustine—lymphatic system cancer	0.00243	0.00363	CcSEcCtD
Pethidine—Oedema—Bleomycin—lymphatic system cancer	0.00242	0.00363	CcSEcCtD
Pethidine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00242	0.00363	CcSEcCtD
Pethidine—Erythema—Mitoxantrone—lymphatic system cancer	0.00241	0.00361	CcSEcCtD
Pethidine—Vomiting—Teniposide—lymphatic system cancer	0.00239	0.00358	CcSEcCtD
Pethidine—Agitation—Carmustine—lymphatic system cancer	0.00238	0.00356	CcSEcCtD
Pethidine—Asthenia—Fludarabine—lymphatic system cancer	0.00237	0.00355	CcSEcCtD
Pethidine—Rash—Teniposide—lymphatic system cancer	0.00237	0.00355	CcSEcCtD
Pethidine—Dermatitis—Teniposide—lymphatic system cancer	0.00237	0.00354	CcSEcCtD
Pethidine—Headache—Teniposide—lymphatic system cancer	0.00236	0.00353	CcSEcCtD
Pethidine—Pruritus—Fludarabine—lymphatic system cancer	0.00234	0.0035	CcSEcCtD
Pethidine—Anorexia—Bleomycin—lymphatic system cancer	0.00231	0.00346	CcSEcCtD
Pethidine—Agitation—Vincristine—lymphatic system cancer	0.00227	0.0034	CcSEcCtD
Pethidine—Hypotension—Bleomycin—lymphatic system cancer	0.00227	0.00339	CcSEcCtD
Pethidine—Convulsion—Carmustine—lymphatic system cancer	0.00225	0.00336	CcSEcCtD
Pethidine—Hypertension—Carmustine—lymphatic system cancer	0.00224	0.00335	CcSEcCtD
Pethidine—Nausea—Teniposide—lymphatic system cancer	0.00223	0.00334	CcSEcCtD
Pethidine—Vertigo—Vincristine—lymphatic system cancer	0.00222	0.00333	CcSEcCtD
Pethidine—Anxiety—Carmustine—lymphatic system cancer	0.0022	0.00329	CcSEcCtD
Pethidine—Convulsion—Vincristine—lymphatic system cancer	0.00214	0.00321	CcSEcCtD
Pethidine—Hypertension—Vincristine—lymphatic system cancer	0.00214	0.0032	CcSEcCtD
Pethidine—Confusional state—Carmustine—lymphatic system cancer	0.00213	0.00319	CcSEcCtD
Pethidine—Oedema—Carmustine—lymphatic system cancer	0.00212	0.00317	CcSEcCtD
Pethidine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00211	0.00315	CcSEcCtD
Pethidine—Visual disturbance—Methotrexate—lymphatic system cancer	0.0021	0.00315	CcSEcCtD
Pethidine—Vomiting—Fludarabine—lymphatic system cancer	0.0021	0.00314	CcSEcCtD
Pethidine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00209	0.00312	CcSEcCtD
Pethidine—Rash—Fludarabine—lymphatic system cancer	0.00209	0.00312	CcSEcCtD
Pethidine—Dermatitis—Fludarabine—lymphatic system cancer	0.00208	0.00312	CcSEcCtD
Pethidine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00208	0.00311	CcSEcCtD
Pethidine—Headache—Fludarabine—lymphatic system cancer	0.00207	0.0031	CcSEcCtD
Pethidine—Tachycardia—Carmustine—lymphatic system cancer	0.00207	0.00309	CcSEcCtD
Pethidine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00205	0.00306	CcSEcCtD
Pethidine—Oedema—Vincristine—lymphatic system cancer	0.00202	0.00302	CcSEcCtD
Pethidine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00202	0.00302	CcSEcCtD
Pethidine—Anorexia—Carmustine—lymphatic system cancer	0.00202	0.00302	CcSEcCtD
Pethidine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.002	0.00299	CcSEcCtD
Pethidine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00198	0.00297	CcSEcCtD
Pethidine—Hypotension—Carmustine—lymphatic system cancer	0.00198	0.00296	CcSEcCtD
Pethidine—Oedema—Mitoxantrone—lymphatic system cancer	0.00197	0.00294	CcSEcCtD
Pethidine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00197	0.00294	CcSEcCtD
Pethidine—Nausea—Fludarabine—lymphatic system cancer	0.00196	0.00294	CcSEcCtD
Pethidine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00195	0.00292	CcSEcCtD
Pethidine—Shock—Mitoxantrone—lymphatic system cancer	0.00194	0.00289	CcSEcCtD
Pethidine—Urticaria—Bleomycin—lymphatic system cancer	0.00193	0.00288	CcSEcCtD
Pethidine—Anorexia—Vincristine—lymphatic system cancer	0.00193	0.00288	CcSEcCtD
Pethidine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00192	0.00287	CcSEcCtD
Pethidine—Insomnia—Carmustine—lymphatic system cancer	0.00191	0.00286	CcSEcCtD
Pethidine—Irritability—Methotrexate—lymphatic system cancer	0.0019	0.00285	CcSEcCtD
Pethidine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.0019	0.00284	CcSEcCtD
Pethidine—Mood swings—Methotrexate—lymphatic system cancer	0.00189	0.00283	CcSEcCtD
Pethidine—Hypotension—Vincristine—lymphatic system cancer	0.00189	0.00282	CcSEcCtD
Pethidine—Somnolence—Carmustine—lymphatic system cancer	0.00188	0.00281	CcSEcCtD
Pethidine—Anorexia—Mitoxantrone—lymphatic system cancer	0.00188	0.0028	CcSEcCtD
Pethidine—Decreased appetite—Carmustine—lymphatic system cancer	0.00184	0.00275	CcSEcCtD
Pethidine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00184	0.00275	CcSEcCtD
Pethidine—Insomnia—Vincristine—lymphatic system cancer	0.00183	0.00273	CcSEcCtD
Pethidine—Constipation—Carmustine—lymphatic system cancer	0.00181	0.00271	CcSEcCtD
Pethidine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00179	0.00267	CcSEcCtD
Pethidine—Decreased appetite—Vincristine—lymphatic system cancer	0.00176	0.00263	CcSEcCtD
Pethidine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00175	0.00262	CcSEcCtD
Pethidine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00174	0.00261	CcSEcCtD
Pethidine—Asthenia—Bleomycin—lymphatic system cancer	0.00174	0.0026	CcSEcCtD
Pethidine—Constipation—Vincristine—lymphatic system cancer	0.00173	0.00258	CcSEcCtD
Pethidine—Pruritus—Bleomycin—lymphatic system cancer	0.00172	0.00257	CcSEcCtD
Pethidine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00171	0.00256	CcSEcCtD
Pethidine—Constipation—Mitoxantrone—lymphatic system cancer	0.00168	0.00252	CcSEcCtD
Pethidine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00162	0.00242	CcSEcCtD
Pethidine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00156	0.00234	CcSEcCtD
Pethidine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00156	0.00233	CcSEcCtD
Pethidine—Vomiting—Bleomycin—lymphatic system cancer	0.00154	0.00231	CcSEcCtD
Pethidine—Drowsiness—Methotrexate—lymphatic system cancer	0.00154	0.0023	CcSEcCtD
Pethidine—Rash—Bleomycin—lymphatic system cancer	0.00153	0.00229	CcSEcCtD
Pethidine—Dermatitis—Bleomycin—lymphatic system cancer	0.00153	0.00228	CcSEcCtD
Pethidine—Asthenia—Carmustine—lymphatic system cancer	0.00152	0.00227	CcSEcCtD
Pethidine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00149	0.00223	CcSEcCtD
Pethidine—Sweating—Methotrexate—lymphatic system cancer	0.00147	0.0022	CcSEcCtD
Pethidine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00145	0.00217	CcSEcCtD
Pethidine—Asthenia—Vincristine—lymphatic system cancer	0.00145	0.00217	CcSEcCtD
Pethidine—Nausea—Bleomycin—lymphatic system cancer	0.00144	0.00215	CcSEcCtD
Pethidine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00141	0.00211	CcSEcCtD
Pethidine—Dizziness—Carmustine—lymphatic system cancer	0.0014	0.00209	CcSEcCtD
Pethidine—Vomiting—Carmustine—lymphatic system cancer	0.00135	0.00201	CcSEcCtD
Pethidine—Dizziness—Vincristine—lymphatic system cancer	0.00134	0.002	CcSEcCtD
Pethidine—Rash—Carmustine—lymphatic system cancer	0.00133	0.002	CcSEcCtD
Pethidine—Dermatitis—Carmustine—lymphatic system cancer	0.00133	0.00199	CcSEcCtD
Pethidine—Visual impairment—Methotrexate—lymphatic system cancer	0.00133	0.00199	CcSEcCtD
Pethidine—Headache—Carmustine—lymphatic system cancer	0.00133	0.00198	CcSEcCtD
Pethidine—Vomiting—Vincristine—lymphatic system cancer	0.00128	0.00192	CcSEcCtD
Pethidine—Rash—Vincristine—lymphatic system cancer	0.00127	0.00191	CcSEcCtD
Pethidine—Dermatitis—Vincristine—lymphatic system cancer	0.00127	0.0019	CcSEcCtD
Pethidine—Headache—Vincristine—lymphatic system cancer	0.00127	0.00189	CcSEcCtD
Pethidine—Nausea—Carmustine—lymphatic system cancer	0.00126	0.00188	CcSEcCtD
Pethidine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00125	0.00187	CcSEcCtD
Pethidine—Rash—Mitoxantrone—lymphatic system cancer	0.00124	0.00186	CcSEcCtD
Pethidine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00124	0.00185	CcSEcCtD
Pethidine—Headache—Mitoxantrone—lymphatic system cancer	0.00123	0.00184	CcSEcCtD
Pethidine—Erythema—Methotrexate—lymphatic system cancer	0.0012	0.0018	CcSEcCtD
Pethidine—Nausea—Vincristine—lymphatic system cancer	0.0012	0.00179	CcSEcCtD
Pethidine—Nausea—Mitoxantrone—lymphatic system cancer	0.00117	0.00175	CcSEcCtD
Pethidine—Vertigo—Methotrexate—lymphatic system cancer	0.00108	0.00161	CcSEcCtD
Pethidine—Convulsion—Methotrexate—lymphatic system cancer	0.00104	0.00156	CcSEcCtD
Pethidine—Confusional state—Methotrexate—lymphatic system cancer	0.000988	0.00148	CcSEcCtD
Pethidine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00098	0.00147	CcSEcCtD
Pethidine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000948	0.00142	CcSEcCtD
Pethidine—Anorexia—Methotrexate—lymphatic system cancer	0.000934	0.0014	CcSEcCtD
Pethidine—Hypotension—Methotrexate—lymphatic system cancer	0.000916	0.00137	CcSEcCtD
Pethidine—Insomnia—Methotrexate—lymphatic system cancer	0.000887	0.00133	CcSEcCtD
Pethidine—Somnolence—Methotrexate—lymphatic system cancer	0.000871	0.0013	CcSEcCtD
Pethidine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000852	0.00127	CcSEcCtD
Pethidine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000808	0.00121	CcSEcCtD
Pethidine—Urticaria—Methotrexate—lymphatic system cancer	0.000779	0.00116	CcSEcCtD
Pethidine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000722	0.00108	CcSEcCtD
Pethidine—Asthenia—Methotrexate—lymphatic system cancer	0.000703	0.00105	CcSEcCtD
Pethidine—Pruritus—Methotrexate—lymphatic system cancer	0.000694	0.00104	CcSEcCtD
Pethidine—Dizziness—Methotrexate—lymphatic system cancer	0.000648	0.000969	CcSEcCtD
Pethidine—Vomiting—Methotrexate—lymphatic system cancer	0.000623	0.000932	CcSEcCtD
Pethidine—Rash—Methotrexate—lymphatic system cancer	0.000618	0.000924	CcSEcCtD
Pethidine—Dermatitis—Methotrexate—lymphatic system cancer	0.000618	0.000923	CcSEcCtD
Pethidine—Headache—Methotrexate—lymphatic system cancer	0.000614	0.000918	CcSEcCtD
Pethidine—Nausea—Methotrexate—lymphatic system cancer	0.000582	0.000871	CcSEcCtD
